Brought to you by 
Epirus grants Livzon Mabpharm license to BOW015 in China and Taiwan
02 Feb 2023
Executive Summary
Five months after reverse merging with Zalicus, Epirus Biopharmaceuticals Inc. (developing biosimilar monoclonal antibodies) has signed on Chinese biotech Livzon Mabpharm Inc. (a subsidiary of Livzon Pharmaceutical Group Inc.) to help develop, manufacture, and commercialize up to five biosimilar antibody drugs.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Epirus grants Livzon Mabpharm license to BOW015 in China and Taiwan
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice